News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Bettina Ryll: Valerie Diane Valeriano at MPNE Hubs 2024 on how the microbiome modulates response to immune therapies in Melanoma
Valerie Diane Valeriano and Bettina Ryll
Dec 9, 2024, 14:45

Bettina Ryll: Valerie Diane Valeriano at MPNE Hubs 2024 on how the microbiome modulates response to immune therapies in Melanoma

Bettina Ryll, Founder of MPN Europe, shared on LinkedIn:

“Listening to Valerie Diane Valeriano at MPNEhubs 2024 on how the microbiome modulates response to immune therapies in Melanoma and her work in the OncoBiome project.

A lot of considerations to turn an observation into something that could become a treatment a scale- and why designer microbiome consortia might be a good concept.

If you want to meet someone passionate about microbiota- you have to meet Valerie Diane Valeriano.”

Bettina Ryll

 Article 1: Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients

Bettina Ryll

Article 2: Genomic heterogeneity and ploidy identify patients with intrinsic resistance to PD-1 blockade in metastatic melanoma

Bettina Ryll

More posts featuring Bettina Ryll.

anti-PD-1 therapy Bettina Ryll cancer Fecal microbiota Genomic heterogeneity Melanoma melanoma patients metastatic melanoma microbiome microbiota MPNEhubs OncoDaily Oncology patients ploidy identify Valerie Diane Valeriano
Special Coverage
Insight
Dec 9, 2024, 14:45
Bettina Ryll: Valerie Diane Valeriano at MPNE Hubs 2024 on how the microbiome modulates response to immune therapies in Melanoma
Blog
Dec 9, 2024, 14:41
Together, We Rise, Prevail and Save Lives - European Liver Patients' Association
Blog
Dec 9, 2024, 14:41
Why is Cancer Awareness Month Important? - SHRO
Blog
Dec 9, 2024, 14:39
Tom Powles: Terry Friedlander highlights multiple factors why SG did not beat chemotherapy in UC
Blog
Dec 9, 2024, 14:38
Angela Lamarca: Pleasured to co-chair a Mini Oral ESMO Asia24 session
Blog
Dec 9, 2024, 14:37
Brittney Abernathy: ESMO Asia has been a whirlwind
Blog
Dec 9, 2024, 14:36
Andrew Albert and Craig Eagle discuss the new SHIELD screening blood test for colon cancer - Doctor Podcasts
Blog
Dec 9, 2024, 14:35
Veli Bakalov: My first investigator-initiated clinical trial is now open for enrollment
Insight
Dec 9, 2024, 14:30
Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory Multiple Myeloma
Insight
Dec 9, 2024, 14:27
Sanjay Popat: The Pan-Asian adapted ESMO Clinical Practice Guidelines for Oncogene Addicted Metastatic NSCLC
Blog
Dec 9, 2024, 14:25
Christine Lovly: Striving to overcome MRD observed with Targeted Therapy in Lung Cancer
Blog
Dec 9, 2024, 14:21
Omali Pitiyarachchi: Prof Zarnie Lwin – updates in the treatment of gliomas